S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
NASDAQ:GLMD

Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

$0.29
-0.01 (-3.31%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.29
$0.31
50-Day Range
$0.30
$0.47
52-Week Range
$0.29
$2.73
Volume
20,104 shs
Average Volume
89,693 shs
Market Capitalization
$7.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Galmed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,566.7% Upside
$5.00 Price Target
Short Interest
Healthy
0.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Galmed Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.73) to ($0.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

GLMD stock logo

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

Galmed Pharmaceuticals Shares Down 16%
Galmed Pharmaceuticals's Earnings Outlook
See More Headlines
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Company Calendar

Last Earnings
11/08/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
5/01/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,612.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-32,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.63 per share

Miscellaneous

Free Float
N/A
Market Cap
$7.32 million
Optionable
Optionable
Beta
1.51

Key Executives

  • Mr. Allen Baharaff (Age 57)
    Co-Founder, Pres, CEO & Chairman
    Comp: $1.71M
  • Mr. Guy Nehemya (Age 37)
    COO & Data Protection Officer
    Comp: $168.93k
  • Mr. Yohai Stenzler CPA (Age 39)
    Chief Accounting Officer
    Comp: $173.11k
  • Dr. Liat Hayardeny (Age 55)
    Chief Scientific Officer
    Comp: $263.01k
  • Mr. Doron Cohen (Age 55)
    Chief Financial Officer
  • Ms. Yael Hollander (Age 39)
    VP of Legal Affairs & Strategy
  • Ms. Shani Ganon
    HR Mang.
  • Dr. Tali Gorfine (Age 52)
    Medical Consultant
  • Mr. Niv Alon
    Head of PMO













GLMD Stock - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View GLMD analyst ratings
or view top-rated stocks.

What is Galmed Pharmaceuticals' stock price forecast for 2023?

5 Wall Street analysts have issued 12-month price objectives for Galmed Pharmaceuticals' stock. Their GLMD share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,612.9% from the stock's current price.
View analysts price targets for GLMD
or view top-rated stocks among Wall Street analysts.

How have GLMD shares performed in 2022?

Galmed Pharmaceuticals' stock was trading at $1.82 at the beginning of 2022. Since then, GLMD stock has decreased by 84.0% and is now trading at $0.2919.
View the best growth stocks for 2022 here
.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 18,300 shares, a decrease of 45.9% from the October 31st total of 33,800 shares. Based on an average daily volume of 41,100 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the shares of the stock are short sold.
View Galmed Pharmaceuticals' Short Interest
.

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our GLMD earnings forecast
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.04.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $0.29.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $7.32 million. The biopharmaceutical company earns $-32,470,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.

This page (NASDAQ:GLMD) was last updated on 11/30/2022 by MarketBeat.com Staff